Search research articles
Contact Us
Filters
Showing results (91-100 of 172) with videos related to
Page
of 18
Sort By:
Scandinavian Journal of Gastroenterology
|
February 15, 2002
Absence of therapeutic efficacy of the somatostatin analogue lanreotide in advanced primary hepatic cholangiocellular cancer and adenocarcinoma of the gallbladder despite in vivo somatostatin-receptor expression
W C Fiebiger, W Scheithauer, T Traub, et al.
Der Chirurg; Zeitschrift Fur Alle Gebiete Der Operativen Medizen
|
October 12, 2001
[Determination of therapy management in rectal carcinoma by staging with 18-FDG-PET]
S Mirzaei, A U Schratter-Sehn, P Knoll, et al.
European Journal of Gastroenterology & Hepatology
|
November 27, 1998
Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial
C Müller, S Pongratz, J Pidlich, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
June 1, 1997
Vasoactive intestinal peptide and somatostatin receptor scintigraphy for differential diagnosis of hepatic carcinoid metastasis
A Kurtaran, M Raderer, C Müller, et al.
Cancer Genetics and Cytogenetics
|
September 2, 1998
Cytogenetic analysis and fluorescence in situ hybridization in a case of IgD multiple myeloma
G Weinländer, J Drach, M Raderer, et al.
Onkologie
|
July 8, 2003
Second-line treatment of advanced gastric cancer with oxaliplatin plus raltitrexed
K E Schmid, G V Kornek, B Schüll, et al.
Anti-Cancer Drugs
|
November 18, 2000
Phase II study of second-line oxaliplatin, irinotecan and mitomycin C in patients with advanced or metastatic colorectal cancer
M Hejna, W J Köstler, M Raderer, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 13, 2001
Decrease of duration and symptoms in chemotherapy-induced oral mucositis by topical GM-CSF: results of a prospective randomised trial
M Hejna, W J Köstler, M Raderer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 15, 2002
Chemotherapy for management of localised high-grade gastric B-cell lymphoma: how much is necessary?
M Raderer, A Chott, J Drach, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 10, 1999
Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer
W Scheithauer, G V Kornek, M Raderer, et al.
Page
of 18
Search research articles
Search
Showing results (91-100 of 172) with videos related to
Sort By:
Page
of 18
Scandinavian Journal of Gastroenterology
|
February 15, 2002
Absence of therapeutic efficacy of the somatostatin analogue lanreotide in advanced primary hepatic cholangiocellular cancer and adenocarcinoma of the gallbladder despite in vivo somatostatin-receptor expression
W C Fiebiger, W Scheithauer, T Traub, et al.
Der Chirurg; Zeitschrift Fur Alle Gebiete Der Operativen Medizen
|
October 12, 2001
[Determination of therapy management in rectal carcinoma by staging with 18-FDG-PET]
S Mirzaei, A U Schratter-Sehn, P Knoll, et al.
European Journal of Gastroenterology & Hepatology
|
November 27, 1998
Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial
C Müller, S Pongratz, J Pidlich, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
June 1, 1997
Vasoactive intestinal peptide and somatostatin receptor scintigraphy for differential diagnosis of hepatic carcinoid metastasis
A Kurtaran, M Raderer, C Müller, et al.
Cancer Genetics and Cytogenetics
|
September 2, 1998
Cytogenetic analysis and fluorescence in situ hybridization in a case of IgD multiple myeloma
G Weinländer, J Drach, M Raderer, et al.
Onkologie
|
July 8, 2003
Second-line treatment of advanced gastric cancer with oxaliplatin plus raltitrexed
K E Schmid, G V Kornek, B Schüll, et al.
Anti-Cancer Drugs
|
November 18, 2000
Phase II study of second-line oxaliplatin, irinotecan and mitomycin C in patients with advanced or metastatic colorectal cancer
M Hejna, W J Köstler, M Raderer, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 13, 2001
Decrease of duration and symptoms in chemotherapy-induced oral mucositis by topical GM-CSF: results of a prospective randomised trial
M Hejna, W J Köstler, M Raderer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 15, 2002
Chemotherapy for management of localised high-grade gastric B-cell lymphoma: how much is necessary?
M Raderer, A Chott, J Drach, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 10, 1999
Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer
W Scheithauer, G V Kornek, M Raderer, et al.
Page
of 18